Celgene walks away from Oncomed’s navicixizumab
Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
Read More
Tag: VEGF
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read More
NICE widens scope of Bayer’s Eylea
Cost regulators are now backing NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
